Table 4 Phagocytosis check point targeting drugs in clinical trial (registered in China) and IND stage
From: Emerging phagocytosis checkpoints in cancer immunotherapy
Company Name(sponsor) | Drug name | main component | Target | Disease | Clinical phase | Conbination drug | single-drug therapy or combination therapy | National Clinical Request Number (CTR NO.) |
|---|---|---|---|---|---|---|---|---|
3D Medicines/ImmuneOncia Therapeutics | 3D-197/IMC-002 | Monoclonal Antibody | CD47 | Solid Tumor/Lymphoma | Phase 1 | single-drug therapy | CTR20220544 | |
Akeso | AK117 | Monoclonal Antibody | CD47 | Advanced Malignancies | Phase 1/2 | AK112 | combination therapy | CTR20220121 |
Advanced Malignancies | Phase 1/2 | AK112 | combination therapy | CTR20212989 | ||||
Advanced Malignancies | Phase 1/2 | AK104 | combination therapy | CTR20220284 | ||||
BioRay | BR105 | Monoclonal Antibody | SIRPα | Advanced Malignancies | Phase 1 | single-drug therapy | CTR20220467 | |
Bio-Thera Solutions | BAT7104 | bispecific antibody | CD47/PDL1 | Advanced Malignancies | Phase 1 | single-drug therapy | CTR20220098 | |
Chia Tai Tianqing | TQB2928 | Monoclonal Antibody | CD47 | Advanced Malignancies | Phase 1 | single-drug therapy | CTR20213324 | |
GeneScience | gentulizumab | Monoclonal Antibody | CD47 | Hematological Malignancy | Phase 1 | single-drug therapy | CTR20210066 | |
Hengrui Pharmaceutical | SHR-1603 | Monoclonal Antibody | CD47 | Advanced Malignancies | Phase 1 | not declared publically | CTR20181964,stopped | |
ImmuneOnco Biopharma | IMM01 | Fusion protein | CD47 | Lymphoma | Phase 1 | not declared publically | CTR20191531 | |
HL/B-NHL/AML/MDS/MM | Phase 2 | single-drug therapy | CTR20212227 | |||||
AML/MDS | Phase 1 | Azacitidine | combination therapy | CTR20212519 | ||||
Solid Tumor | Phase 1/2 | BGB-A317 | combination therapy | CTR20220791 | ||||
IMM0306 | bispecific antibody | CD47/CD20 | NHL | Phase 1 | not declared publically | CTR20192612 | ||
IMM2902 | bispecific antibody | CD47/SIRPα | Solid Tumor | Phase 1 | single-drug therapy | CTR20212375 | ||
Innovent | IBI188/Letaplimab | Monoclonal Antibody | CD47 | Advanced Malignancies | Phase 1 | single-drug therapy | CTR20210761 | |
Advanced Malignancies | Phase 1 | not declared publically | CTR20182140 | |||||
AML | Phase 1/2 | Azacitidine/Decitabine | single-drug therapy and combination therapy | CTR20200938 | ||||
MDS | Phase 1/3 | Azacitidine | combination therapy | CTR20201039 | ||||
IBI322 | bispecific antibody | CD47/PDL1 | Advanced Malignancies | Phase 1 | Bevacizumab/Docetaxel | single-drug therapy and combination therapy | CTR20200175 | |
Solid Tumor | Phase 1 | Sintilimab/Bevacizumab | single-drug therapy and combination therapy | CTR20211251 | ||||
Hematological Malignancy | Phase 1 | single-drug therapy | CTR20210385 | |||||
Myeloid Malignancies | Phase 1 | single-drug therapy | CTR20213120 | |||||
IBI397 | Advanced Malignancies | Phase 1 | single-drug therapy | CTR20220193 | ||||
ZL-1201 | Monoclonal Antibody | CD47 | Solid Tumor or Hematological Malignancy | Phase 1 | single-drug therapy | CTR20210973 | ||
JMT BIO | JMT601 | Fusion protein | CD20/CD47 | NHL | Phase 1 | single-drug therapy | CTR20211365 | |
Mabwell | 6MW3211 | bispecific antibody | CD47/PDL1 | Advanced Malignancies | Phase 1/2 | single-drug therapy | CTR20211936 | |
SUMGEN | SG12473 | bispecific antibody | CD47/PDL1 | Advanced Malignancies | Phase 1 | single-drug therapy | CTR20211029 | |
SG404 | Fusion protein | CD47 | Advanced Malignancies | Phase 1 | single-drug therapy | CTR20202489 | ||
SUNHO (China) | IBC0966 | bispecific antibody | CD47/PDL1 | Advanced Malignancies | Phase 1/2 | single-drug therapy | CTR20211609 | |
Waterstone | HX009 | bispecific antibody | CD47/PD1 | Solid Tumor | Phase 2 | single-drug therapy | CTR20211292 | |
Solid Tumor | Phase 1 | not declared publically | CTR20192299 | |||||
Lymphoma | Phase 1/2 | single-drug therapy | CTR20213391 | |||||
Shandong New Time Pharmaceutical | F527 | Monoclonal Antibody | CD47 | Lymphoma | Phase 1 | single-drug therapy | CTR20220738 | |
MAB WORKS | MIL95 | Monoclonal Antibody | CD47 | Solid Tumor or Hematological Malignancy | Phase 1 | single-drug therapy | CTR20201108 | |
SUNHO | IBC0966 | bispecific antibody | CD47/PDL1 | Advanced Malignant Tumors | Phase 2 | single-drug therapy | NCT04980690 | |
Shenzhen Geno-Immune Medical Institute | Sarcoma-specific CAR-T cells | CAR-T | GD2 | Sarcoma, Osteoid Sarcoma, Ewing Sarcoma | Phase 2 | single-drug therapy | NCT03356782 | |
Xuanwu Hospital, Beijing | GD2-CAR-T cells | CAR-T | GD2 | Glioma,Malignant Glioma of Brain,Recurrence Tumor | Phase 1 | single-drug therapy | NCT03423992 |
